<DOC>
	<DOC>NCT01968954</DOC>
	<brief_summary>This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.</brief_summary>
	<brief_title>Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Treated with a statin. Fasting LDLC &gt; 70 mg/dL and triglyceride &lt;=400 mg/dL. High or very high risk of incurring a cardiovascular event. Pregnant or breastfeeding females. Cardiovascular or cerebrovascular event of procedures during the past 30 days. Congestive heart failure NYHA class IV. Poorly controlled hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>mixed dyslipidemia</keyword>
	<keyword>high risk of cardiovascular events</keyword>
</DOC>